Transgene (LTS:0OCQ) Long-Term Debt: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCQ Transgene SA LTS:0OCQ
49 GF Score
Price €0.73
GF Value €0.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Long-Term Debt?

Transgene LTS:0OCQ +0.27% 49 Long-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus rates LTS:0OCQ with a GF Score™ of 49/100 and a GF Value™ of €0.52 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Transgene's Long-Term Debt for the quarter that ended in Dec. 2025 was €0.00 Mil.

Transgene  (LTS:0OCQ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Transgene Long-Term Debt Related Terms

Transgene Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Transgene's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Long-Term Debt Chart

Transgene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Transgene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0OCQ
49GF Score
Transgene SA LTS:0OCQ
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Transgene (LTS:0OCQ) has a Long-Term Debt of €0.00 Mil as of Dec. 2025.
Is Transgene's Long-Term Debt too high?
Transgene's current Long-Term Debt is €0.00 Mil. Overall, Transgene has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's Long-Term Debt compare to VRTX and REGN?
Transgene's Long-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Transgene's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (LTS:0OCQ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.52, compared to a current price of €0.73 — trading 41.2% above its estimated fair value. The current Long-Term Debt is €0.00 Mil. Transgene's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Transgene (LTS:0OCQ), the current Long-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene (LTS:0OCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.73 is trading 41.2% above its estimated GF Value™ of €0.52. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for LTS:0OCQ:

  • Long-Term Debt: €0.00 Mil
  • GF Value™: €0.52 vs. price of €0.73 (41.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the LTS:0OCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
49GF Score

Get the complete analysis for LTS:0OCQ

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.73
Price
€0.52
GF Value